ThermoGenesis Holdings stock (US88603Y1055): Pioneering cell and gene therapy solutions

ThermoGenesis Holdings develops automated systems for cell processing used in therapies targeting blood, cancer, and autoimmune diseases. US investors track the company for its role in the expanding regenerative medicine sector.

ThermoGenesis Holdings focuses on innovative technologies for cell and gene therapy processing. The company provides automated, closed systems that enable point-of-care processing of stem cells and other therapeutic cells. These solutions support treatments for blood disorders, cancers, and immune conditions, addressing key needs in regenerative medicine.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: ThermoGenesis Holdings
• Sector/industry: Biotechnology / Cell Therapy Equipment
• Headquarters/country: United States
• Core markets: Regenerative medicine, cell processing
• Key revenue drivers: Automated cell processing systems, consumables
• Home exchange/listing venue: Nasdaq (THMO)
• Trading currency: USD

ThermoGenesis Holdings: core business model

ThermoGenesis Holdings develops and sells medical devices for the collection, processing, and storage of hematopoietic stem cells and other therapeutic cells. Its flagship products include the Semi-Automated Semi and the fully automated AXP II systems, which perform density gradient separation and point-of-care processing. These enable clinicians to prepare cells for autologous therapies directly at treatment sites, reducing logistical challenges in cell therapy workflows.

The business model centers on selling capital equipment alongside recurring revenue from proprietary disposable kits and accessories. This razor-and-blade approach supports predictable income streams as therapy volumes grow. The company targets hospitals, clinics, and cord blood banks worldwide, with a focus on applications in oncology and orthopedics.

Main revenue and product drivers for ThermoGenesis Holdings

Primary revenue comes from the sale of processing systems and single-use processing sets. The AXP AutoEx device processes umbilical cord blood into high-dose stem cell products for transplants. BioArchive offers cryogenic storage solutions for long-term cell preservation. In fiscal 2024, reported as of May 2025, product sales accounted for the majority of revenue, supplemented by service contracts.

Key growth drivers include rising demand for CAR-T cell therapies and stem cell transplants. ThermoGenesis systems integrate with these workflows, providing GMP-compliant processing. Expansion into emerging markets like Asia supports volume growth for consumables.

ThermoGenesis Holdings matters for US investors

Listed on Nasdaq, ThermoGenesis Holdings offers US investors exposure to the cell and gene therapy boom. The US leads in FDA approvals for advanced therapies, driving demand for processing tech. With over 50% of global CAR-T treatments in the US, the company's equipment plays a direct role in this high-growth market valued at billions annually.

Conclusion

ThermoGenesis Holdings positions itself at the intersection of biotech innovation and clinical application through its cell processing platforms. Ongoing advancements in regenerative therapies sustain interest from US investors seeking exposure to this dynamic sector. Market adoption of automated systems remains a key watchpoint for future developments.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.